curcumin | 147556-16-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: curcumin
• 英文别名: (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one；diferuloylmethane
• CAS: 147556-16-9
• 化学式: C₂₁H₂₀O₆
• 分子量: 368.386
• InChiKey: ZIUSSTSXXLLKKK-KOBPDPAPSA-N

物化性质

• 熔点：
  181-182 °C(Solv: acetone (67-64-1))
• 沸点：
  593.2±50.0 °C(Predicted)
• 密度：
  1.307±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  96.2
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  curcumin 在 盐酸羟胺 作用下， 以 乙醇 为溶剂， 生成 3,5-bis(4-hydroxy-3-methoxystyryl)isoxazole
  参考文献：
  名称：

  Antitumor effects of curcumin and structurally β-diketone modified analogs on multidrug resistant cancer cells

  摘要：

  Using concepts of bioisostery a series of curcumin analogs were synthesized: the diketonic system of the compound was elaborated into enamitiones, oximes, and the isoxazole heterocycle. The cell growth inhibitory and apoptosis inducing effects of the new analogs were evaluated by in vitro assays in the hepatocellular carcinoma HA22T/VGH cells, as well as in the MCF-7 breast cancer cell line and in its multidrug resistant (MDR) variant MCF-7R. Increased antitumor activity on all cell lines was found with the isoxazole analog and especially with the benzyl oxime derivative; in the HA22T/VGH cell model, the latter compound inhibited constitutive NF-kappa B activation. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.021
• 作为产物：
  描述：

  姜黄素 在 盐酸 作用下， 以 水 为溶剂， 生成 curcumin
  参考文献：
  名称：

  Synthesis and Identification of New 4-Arylidene Curcumin Analogues as Potential Anticancer Agents Targeting Nuclear Factor-κB Signaling Pathway

  摘要：

  A series of curcumin analogues including new 4-arylidene curcumin analogues (4-arylidene-1,7-bisarylhepta-1,6-diene-3,5-diones) were synthesized. Cell growth inhibition assays revealed that most 4-arylidene curcumin analogues can effectively decrease the growth of a panel of lung cancer cells at submicromolar and low micromolar concentrations. High content analysis technology coupled with biochemical studies showed that this new class of 4-arylidene curcumin analogues exhibits significantly improved NF-kappa B inhibition activity over the parent compound curcumin, at least in part by inhibiting I kappa B phosphorylation and degradation via IKK blockage; selected 4-arylidene curcumin analogues also reduced the tumorigenic potential of cancer cells in a clonogenic assay.

  DOI：

  10.1021/jm1004545

文献信息

• [EN] ENCAPSULATES<br/>[FR] PRODUITS ENCAPSULÉS
  申请人：PROCTER & GAMBLE

  公开号：WO2013022949A1

  公开（公告）日：2013-02-14

  The present application relates to encapsulates, compositions, products comprising such encapsulates, and processes for making and using such encapsulates. Such encapsulates comprise a core comprising a perfume and a shell that encapsulates said core, such encapsulates may optionally comprise a parametric balancing agent, such shell comprising one or more azobenzene moieties.

  本申请涉及封装体、组合物、包含这种封装体的产品，以及制备和使用这种封装体的方法。这种封装体包括一个包含香水的核心和封装该核心的壳，这种封装体可以选择性地包含一个参数平衡剂，该壳包括一个或多个偶氮苯基团。
• Synthesis, pharmacological profile and 2D-QSAR studies of curcumin-amino acid conjugates as potential drug candidates
  作者：Siva S. Panda、Adel S. Girgis、Sean J. Thomas、Jason E. Capito、Riham F. George、Asmaa Salman、May A. El-Manawaty、Ahmed Samir

  DOI：10.1016/j.ejmech.2020.112293

  日期：2020.6

  good yields utilizing an optimized reaction condition. We explored the effect of different amino acids and protecting groups on biological activities of curcumin. The conjugates were screened for anti-inflammatory, analgesic and antimicrobial properties. Some of the conjugates showed promising biological observations with a potency comparable with the standard references. The variations in biological properties

  利用优化的反应条件，以高收率合成了一系列姜黄素双结合物3a-q，5a-k和6a-k。我们探索了不同氨基酸和保护基对姜黄素生物学活性的影响。筛选缀合物的抗炎，止痛和抗菌特性。一些结合物显示出有希望的生物学观察结果，其效力与标准参考物相当。关于不同氨基酸和保护基的生物学特性的变化是有趣的观察结果。合成的缀合物对脾细胞的影响以及脂多糖刺激的腹膜巨噬细胞产生一氧化氮与观察到的抗炎特性相关。我们还建立了活性最高的结合物的安全性。
• [EN] SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS<br/>[FR] RÉACTIFS DE MÉTHYLFORMYLE SUBSTITUÉ ET PROCÉDÉ D'UTILISATION DE CEUX-CI POUR MODIFIER DES PROPRIÉTÉS PHYSICOCHIMIQUES ET/OU PHARMACOCINÉTIQUES DE COMPOSÉS
  申请人：SPHAERA PHARMA PRIVATE LTD

  公开号：WO2012137225A1

  公开（公告）日：2012-10-11

  The present invention relates to the synthesis and application of novel chiral/ achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.

  本发明涉及合成和应用新型手性/非手性取代甲基甲酰试剂，用于修改药物和/或生物活性物质，以改变未经修改的原始试剂产生的化合物的物理化学、生物学和/或药代动力学性质。
• Aryl fluorosulfate analogues as potent antimicrobial agents: SAR, cytotoxicity and docking studies
  作者：Lekkala Ravindar、S.N.A. Bukhari、K.P. Rakesh、H.M. Manukumar、H.K. Vivek、N. Mallesha、Zhi-Zhong Xie、Hua-Li Qin

  DOI：10.1016/j.bioorg.2018.08.001

  日期：2018.12

  that the antimicrobial activity depends upon the presence of –OSO2F group and slender effect of different substituent’s on the phenyl rings. The electron donating (OCH3) groups in analogs increase the antibacterial activity, and interestingly the electron withdrawing (Cl, NO2, F and Br) groups increase the antifungal activity (except compound 35, 36 and 37). The mechanism of potent compounds showed membrane

  一系列芳基氟代类似物（的1 - 37）的合成和测试体外抗细菌和抗真菌研究，并通过对接研究验证。化合物9、12、14、19、25、26、35、36和37对测试的细菌菌株显示出优异的抗菌效力，而化合物2、4、5、15、35、36和37被发现具有更好的抗真菌活性分别与标准抗生素庆大霉素和酮康唑相比，可抵抗测试的真菌菌株。在所有的合成37点的类似物，化合物25，26，35，3637和37对金黄色葡萄球菌显示出优异的抗生物膜特性。结构-活性关系（SAR）表明，抗菌活性取决于–OSO 2 F基团的存在以及不同取代基对苯环的细长作用。类似物中的给电子基团（OCH 3）增加了抗菌活性，有趣的是，吸电子基团（Cl，NO 2，F和Br）增加了抗真菌活性（化合物35、36和37除外）。SEM证实了强效化合物的作用机理表明其对细菌的膜损伤。化合物35，36和在分子对接研究中，有37个滑翔g得分最高，并证明了其杀生物性质。
• Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration
  申请人：Collman James P.

  公开号：US20110301180A1

  公开（公告）日：2011-12-08

  It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.

  已经发现，在血小板中抑制线粒体呼吸可以减少血小板的激活或血小板聚集。某些杂环化合物显著降低了一个或多个血小板功能，包括凝聚、粘附或血小板刺激的凝血。因此，由血小板激活或血小板聚集水平不当高导致的疾病或疾病可以通过给予一种治疗有效量的杂环化合物或非杂环线粒体抑制剂来治疗，该化合物显著降低了一个或多个血小板功能，包括凝聚、粘附或血小板刺激的凝血，最好是以可逆的方式。

表征谱图